Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset - HMS LINCS Database

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)

Download: Excel (XLSX), Comma-separated (CSV)

Filter results: >>>>

|<
<<
Previous
Page 13 of 18
Next
>>
>
301 to 325 of 432 records
per page:

Cell line	Drug name	Experimental replicate	Timepoint	Curve type (GR values)	Curve type (relative cell counts)	Experiment name	Number of concentrations	Cell doublings (DMSO control)	GR50	GRmax	GR_AOC	GEC50	GRinf	Hill slope (GR values)	R-squared sigmoid fit (GR values)	P-value sigmoid fit (GR values)	R-squared flat fit (GR values)	IC50	Emax	AUC	EC50	Einf	Hill slope (relative cell counts)	R-squared sigmoid fit (relative cell counts)	P-value sigmoid fit (relative cell counts)	R-squared flat fit (relative cell counts)
BT-20	XL147	3	72	flat	flat	BT20 pilaralisib 0 3 72	8	2.647	Inf	0.755	0.102	0.0	0.755	0.01	0.0679	0.81	0.885	Inf	0.708	0.871	0.0	0.708	0.01	0.0505	0.856	0.857
BT-549	AS605240	1	72	sigmoid	sigmoid	BT549 AS-605240 0 1 72	8	1.804	Inf	0.893	0.0436	4.49	0.778	0.375	0.862	0.00261	NA	Inf	0.905	0.961	4.52	0.804	0.371	0.861	0.00267	NA
BT-549	AS605240	2	72	flat	flat	BT549 AS-605240 0 2 72	8	1.961	Inf	0.91	0.0479	0.0	0.91	0.01	0.414	0.201	0.949	Inf	0.914	0.954	0.0	0.914	0.01	0.418	0.197	0.951
BT-549	AS605240	3	72	sigmoid	sigmoid	BT549 AS-605240 0 3 72	8	1.796	Inf	0.863	0.066	4.3	0.721	0.307	0.896	0.00112	NA	Inf	0.881	0.942	4.35	0.756	0.302	0.894	0.00118	NA
BT-549	Alpelisib	1	72	flat	flat	BT549 alpelisib 0 1 72	8	1.822	Inf	0.747	0.0781	0.0	0.747	0.01	0.439	0.176	0.914	Inf	0.782	0.931	0.0	0.782	0.01	0.415	0.2	0.925
BT-549	Alpelisib	2	72	sigmoid	sigmoid	BT549 alpelisib 0 2 72	8	1.927	Inf	0.832	0.0409	4.24	0.663	0.548	0.706	0.0254	NA	Inf	0.844	0.962	4.26	0.686	0.542	0.696	0.0282	NA
BT-549	Alpelisib	3	72	flat	flat	BT549 alpelisib 0 3 72	8	1.743	Inf	0.817	0.068	0.0	0.817	0.01	-0.0192	1.0	0.915	Inf	0.846	0.942	0.0	0.846	0.01	-0.0162	1.0	0.928
BT-549	CAL-101	1	72	sigmoid	sigmoid	BT549 idelalisib 0 1 72	8	1.791	Inf	0.836	0.041	4.8	0.605	0.778	0.924	0.00044	NA	Inf	0.858	0.964	4.79	0.659	0.767	0.92	0.000518	NA
BT-549	Everolimus	2	72	flat	flat	BT549 everolimus 0 2 72	8	1.909	Inf	0.566	0.407	0.0	0.566	0.01	-0.646	1.0	0.594	Inf	0.627	0.648	0.0	0.627	0.01	-1.01	1.0	0.649
BT-549	Everolimus	3	72	sigmoid	flat	BT549 everolimus 0 3 72	8	1.587	59.5	0.533	0.425	1e-05	0.395	0.1	0.702	0.0264	NA	Inf	0.656	0.685	0.0	0.656	0.01	0.48	0.141	0.685
BT-549	KIN001-244	1	72	sigmoid	sigmoid	BT549 KIN001-244 0 1 72	8	1.802	Inf	0.872	0.0273	4.85	0.695	0.794	0.852	0.00324	NA	Inf	0.888	0.976	4.84	0.733	0.786	0.846	0.00362	NA
BT-549	KIN001-244	2	72	sigmoid	sigmoid	BT549 KIN001-244 0 2 72	8	1.920	Inf	0.882	0.00561	2.72	0.793	1.67	0.73	0.0197	NA	Inf	0.89	0.995	2.6	0.813	1.68	0.718	0.0225	NA
BT-549	KIN001-244	3	72	sigmoid	sigmoid	BT549 KIN001-244 0 3 72	8	1.740	Inf	0.861	0.0287	4.69	0.681	0.74	0.922	0.00047	NA	Inf	0.882	0.975	4.7	0.729	0.732	0.919	0.000531	NA
BT-549	MK2206	1	72	sigmoid	sigmoid	BT549 MK-2206 0 1 72	8	1.811	Inf	0.632	0.189	0.103	0.58	0.8	0.911	0.000695	NA	Inf	0.692	0.839	0.101	0.642	0.73	0.911	0.000717	NA
BT-549	MK2206	2	72	sigmoid	sigmoid	BT549 MK-2206 0 2 72	8	1.871	Inf	0.926	0.0188	0.107	0.926	5.0	0.816	0.00627	NA	Inf	0.932	0.983	0.107	0.931	5.0	0.809	0.00694	NA
BT-549	MK2206	3	72	sigmoid	sigmoid	BT549 MK-2206 0 3 72	8	1.685	Inf	0.714	0.131	0.123	0.711	3.44	0.953	0.000102	NA	Inf	0.771	0.895	0.123	0.768	3.25	0.949	0.000136	NA
BT-549	PIK-93	1	72	sigmoid	sigmoid	BT549 PIK-93 0 1 72	8	1.777	Inf	0.691	0.0438	1.77	0.561	1.47	0.989	1.31e-06	NA	Inf	0.742	0.963	1.64	0.646	1.47	0.988	1.83e-06	NA
BT-549	Sirolimus	2	72	flat	flat	BT549 rapamycin 0 2 72	8	1.830	Inf	0.569	0.384	0.0	0.569	0.01	0.517	0.113	0.618	Inf	0.642	0.677	0.0	0.642	0.01	0.465	0.153	0.679
BT-549	Sirolimus	3	72	flat	flat	BT549 rapamycin 0 3 72	8	1.703	Inf	0.455	0.482	0.0	0.455	0.01	0.376	0.243	0.518	Inf	0.582	0.626	0.0	0.582	0.01	0.436	0.179	0.625
BT-549	TGX221	1	72	sigmoid	sigmoid	BT549 TGX-221 0 1 72	8	1.826	Inf	0.821	0.0771	0.297	0.777	0.632	0.868	0.00232	NA	Inf	0.842	0.931	0.313	0.799	0.603	0.863	0.00255	NA
BT-549	Trametinib	2	72	sigmoid	sigmoid	BT549 trametinib 0 2 72	8	1.914	Inf	0.602	0.2	0.0685	0.581	0.837	0.995	1.05e-07	NA	Inf	0.654	0.822	0.0601	0.638	0.839	0.995	1.04e-07	NA
BT-549	Trametinib	3	72	sigmoid	sigmoid	BT549 trametinib 0 3 72	8	1.755	Inf	0.553	0.223	0.107	0.505	0.899	0.942	0.000194	NA	Inf	0.642	0.817	0.104	0.595	0.804	0.938	0.000236	NA
BT-549	XL147	1	72	flat	flat	BT549 pilaralisib 0 1 72	8	1.855	Inf	0.941	0.0385	0.0	0.941	0.01	-0.0931	1.0	0.954	Inf	0.946	0.965	0.0	0.946	0.01	-0.0808	1.0	0.958
BT-549	XL147	2	72	flat	flat	BT549 pilaralisib 0 2 72	8	1.952	Inf	0.967	-0.00824	0.0	0.967	0.01	-0.000427	1.0	1.0	Inf	0.968	1.01	0.0	0.968	0.01	-0.000878	1.0	1.0
BT-549	XL147	3	72	flat	flat	BT549 pilaralisib 0 3 72	8	1.772	Inf	0.933	0.0351	0.0	0.933	0.01	-0.0699	1.0	0.962	Inf	0.941	0.969	0.0	0.941	0.01	-0.0712	1.0	0.967

|<
<<
Previous
Page 13 of 18
Next
>>
>
301 to 325 of 432 records
per page:

HMS LINCS Project

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)